DIUPRE: Diuretics for Postpartum High Blood Pressure in Preeclampsia

Sponsor
Instituto Materno Infantil Prof. Fernando Figueira (Other)
Overall Status
Completed
CT.gov ID
NCT02163655
Collaborator
(none)
120
1
2
17
7.1

Study Details

Study Description

Brief Summary

The purpose of this study is to determine if furosemide administered after the first 24 hours of delivery, in women with severe peeclampsia and eclampsia accelerates high blood pressure control and diminishes hospital stay.

Condition or Disease Intervention/Treatment Phase
Phase 4

Detailed Description

A placebo-controlled study that will be conducted including 120 postpartum women with severe preeclampsia . Women who are previosuly diuretic users, with renal impairment, hemodynamic instability or with contraindications to diuretic use will be excluded. Informed consent will be obtained from all participants . Patients will be randomized to receive furosemide ( 40mg orally every twenty-four hours ) or placebo for maximum of five days. The variables are systolic and diastolic blood pressure, frequency of very high blood pressure, need for maintenance of antihypertensive therapy , number of antihypertensive agents used to control blood pressure , urine output , length of hospital stay , adverse effects and maternal complications . Except for the study drug, patients will receive all care and monitoring according to the hospital protocol and decision to initiate or modify antihypertensive therapy will be defined by the attending physician, as well as the decision to discharge. If the patient is discharged before five days of the protocol drug, this drug will be stopped. Teh patients may decide to leave the study at any moment. Data will be collected by researches daily. Plan statistical analysis will be performed using the public domain program Epi Info 7.0 and the mean and dispersion measures for numerical variables will be calculated. To compare means obtained every day and between groups will be used analysis of variance ( ANOVA ) . Nominal variables were compared using the X2 test or Fisher if necessary. Be considered significant at p < 0,05. The risk ratio (RR) is calculated as a measure of the relative risk for the different outcomes , according to furosemide or placebo

Study Design

Study Type:
Interventional
Actual Enrollment :
120 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Effectiveness of Postpartum Furosemide on Recovery Blood Pressure in Puerperal Women With Severe Preeclampsia: a Randomized Clinical Trial
Study Start Date :
Mar 1, 2014
Actual Primary Completion Date :
Aug 1, 2015
Actual Study Completion Date :
Aug 1, 2015

Arms and Interventions

Arm Intervention/Treatment
Placebo Comparator: PLACEBO

PLACEBO: placebo, oral, every 24 hours for maximum 5 days

Drug: Placebo
Placebo pills, identical to the intervention (furosemide pills), will be administered every 24 hour for a maximum of five days

Experimental: FUROSEMIDE

FUROSEMIDE: 20mg furosemide, oral, every 24 hours for maximum 5 days

Drug: FUROSEMIDE
Furosemide, 20mg pills, will be administered every 24 houras, for a maximum of five days
Other Names:
  • Lasix
  • Outcome Measures

    Primary Outcome Measures

    1. Mean blood pressure [from 24 hours after delivery to first 15 days of delivery]

    Secondary Outcome Measures

    1. postpartum hospital stay [from 24 hours after delivery to 15 days]

      Time until discharge of the hospital

    2. Maintenance of antihypertensive therapy [From 24 hours up to 15 days of delivery]

      Number of antihypertensive agents used to control blood pressure at hospital discharge; time elapsed to control blood pressure; daily urine output; reduction of edema; length of hospital stay; frequency of adverse effects: hypokalemia, polydipsia, headache, mental confusion, muscle pain, tetany, muscle weakness, heart rhythm disturbances and gastrointestinal symptoms; frequency of maternal complications: imminent eclampsia, eclampsia, infection, bleeding manifestations, shock and maternal death.

    3. frequency of adverse effects [From 24 hours to 15 days after delivery]

      Presence of hypokalemia, polydipsia, headache, mental confusion, muscle pain, tetany, muscle weakness, heart rhythm disturbances and gastrointestinal symptoms;

    4. frequency of maternal complications [From 24 hours up to 15 days after delivery]

      Frequency of imminent eclampsia, eclampsia, infection, bleeding manifestations, shock and maternal death.

    Other Outcome Measures

    1. Frequency of very high blood pressure episode [from 24 hours after delivery until 15 days after delivery]

      Frequency of very high blood pressure (Systolic blood pressure >180mmHg and diastolic blood pressure >110mmHg) episodes

    2. Blood pressure control [From 24 hours after delivery to 15 days]

      Absence pf very blood pressure episodes in 24 hours period

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A and Older
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Preeclampsia

    • Urine output > 50ml/h

    • End of postpartum magnesium sulphate

    Exclusion Criteria:
    • Cronic hypertension

    • Bloor pressure < 140mmHg and < 90mmHg

    • Diuretic use

    • Renal impairment

    • Diabetes, sickle cell disease ou rheumatologic disease

    • Hemodinamic instability

    • Potassium < 3mEq/L

    • Contraindications for fusoremide use

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 IMIP Recife Pernambuco Brazil 52020-070

    Sponsors and Collaborators

    • Instituto Materno Infantil Prof. Fernando Figueira

    Investigators

    • Study Director: Leila Katz, MD PhD, IMIP

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Leila Katz, PhD, Instituto Materno Infantil Prof. Fernando Figueira
    ClinicalTrials.gov Identifier:
    NCT02163655
    Other Study ID Numbers:
    • DIUPRE
    • DIUPRE
    First Posted:
    Jun 13, 2014
    Last Update Posted:
    Jul 13, 2021
    Last Verified:
    Jul 1, 2021
    Keywords provided by Leila Katz, PhD, Instituto Materno Infantil Prof. Fernando Figueira
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jul 13, 2021